BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19899132)

  • 1. On being metachromatic: mystique and misunderstanding in mastocytosis.
    Gotlib J
    Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
    Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
    Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of systemic mast cell disease: beyond interferon.
    Tefferi A
    Leuk Res; 2004 Mar; 28(3):223-4. PubMed ID: 14687615
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
    Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
    Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin lesions and mast cells.
    Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
    [No Abstract]   [Full Text] [Related]  

  • 8. [Systemic mastocytosis].
    Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
    Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
    Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical, genetic, and therapeutic insights into systemic mast cell disease.
    Tefferi A; Pardanani A
    Curr Opin Hematol; 2004 Jan; 11(1):58-64. PubMed ID: 14676628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Systemic mastocytosis].
    Metzgeroth G; Schwaab J; Reiter A
    Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1572-5. PubMed ID: 25076308
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.
    Elliott MA; Pardanani A; Li CY; Tefferi A
    Leukemia; 2004 May; 18(5):1027-9. PubMed ID: 15014525
    [No Abstract]   [Full Text] [Related]  

  • 16. [Systemic mastocytosis].
    Sökler M; Kanz L
    Dtsch Med Wochenschr; 2005 Mar; 130(9):474. PubMed ID: 15731964
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic mastocytosis: current classification and novel therapeutic options.
    Barbie DA; Deangelo DJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.